Search results
Once-Promising Drug for Idiopathic Pulmonary Fibrosis Fails in Phase III Trial
MedPage Today· 1 day agoThe fully human monoclonal antibody pamrevlumab failed to improve lung function among patients with idiopathic pulmonary fibrosis (IPF) in the randomized ...
Mirikizumab Shows Promise for Moderate to Severe Crohn's
Medscape· 1 day agoAlready approved for ulcerative colitis, the monoclonal antibody mirikizumab met study endpoints for...
Duoning Collaborates with Bioelectronica to Commercialize a Single-Cell Sorting System for Antibody...
FOX 23 News Albany· 18 hours agoDuoning Biotechnology Group ("Duoning"), a leading one-stop bioprocess provider in China, today...
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
InvestorPlace· 12 hours agoFundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying...
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 6.3% in April
ETF DAILY NEWS· 4 days agoAdagene Inc. (NASDAQ:ADAG – Get Free Report) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 15,100 shares, an increase ...
Sanofi to make €1bn biomanufacturing investment in France
Pharmaceutical Technology via Yahoo Finance· 7 days agoSanofi plans to invest €1bn in Vitry-sur-Seine to construct a new unit in a bid to double the ...
Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks
TipRanks via Yahoo Finance· 2 days agoNew indicators of a cooling economy eased inflation concerns, driving the S&P 500 to record highs...
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis -...
Benzinga· 6 days agoCelldex Therapeutics, Inc. CLDX today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is ...
Abzena at BIO 2024: Showcasing innovation in cell line development technology
BioPharma-Reporter· 6 days agoAbzena has recently launched our AbZelect and AbZelectPRO cell line development (CLD) platforms, to...
Uniquity Bio launches to focus on immunology and inflammation
Pharmaceutical Technology via Yahoo Finance· 5 days agoA monoclonal antibody, solrikitug targets thymic stromal lymphopoietin. It will treat critical...